While many 340B consultants rightly focus their energy on DSH and FQHC optimization, Lisa Nezneski, PharmD, BCPS is doing something entirely different at 340B Orphan Drug Solutions. I highly recommend her expertise to hospital leadership and pharmacy teams at entities governed by the orphan drug exclusion (such as Critical Access Hospitals, Rural Referral Centers, and Sole Community Hospitals). Lisa has zeroed in on a quiet, six-figure revenue leak that standard 340B operations almost always miss: the massive gap between the wholesaler ledger, TPA program eligibility logic, and the FDA OOPD database. When these three distinct systems lack a proper crosswalk, expansion entities leave hundreds of thousands of dollars on the table every single year by default. 100% of the facilities she has reviewed have had this exact exposure. If you are running a rural healthcare facility, Lisa's specialized focus is an absolute game-changer for hospital finance and revenue recovery. Highly recommend checking out the 5-minute diagnostic calculator she built to see exactly where your facility stands.

Steven F. Zielinski, RPh

Executive Healthcare Advisor · Pharmacy Growth Consultant